Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line

Upstream Bio (NASDAQ:UPB) was downgraded by Evercore from an “outperform” rating to an “in-line” rating in a research report issued on Friday. They currently have a $15.00 target price on the stock. Evercore’s target price points to a potential upside of 53.22% from the company’s current price.

Other research analysts have also issued research reports about the company. Mizuho upgraded Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Lifesci Capital initiated coverage on shares of Upstream Bio in a report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Upstream Bio Price Performance

Shares of Upstream Bio stock opened at $9.79 on Friday. The stock has a market capitalization of $529.05 million, a P/E ratio of -5.21 and a beta of 2.96. The business has a 50 day simple moving average of $16.38 and a two-hundred day simple moving average of $21.42. Upstream Bio has a 12 month low of $5.14 and a 12 month high of $33.68.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.06). Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%.The firm had revenue of $0.67 million during the quarter, compared to analyst estimates of $0.52 million. As a group, research analysts anticipate that Upstream Bio will post -4.3 EPS for the current fiscal year.

Institutional Trading of Upstream Bio

Several large investors have recently added to or reduced their stakes in UPB. GF Fund Management CO. LTD. acquired a new stake in shares of Upstream Bio in the 4th quarter worth $29,000. Torren Management LLC acquired a new position in shares of Upstream Bio during the 4th quarter valued at about $30,000. BNP Paribas Financial Markets grew its holdings in shares of Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after purchasing an additional 2,158 shares during the period. Legal & General Group Plc increased its position in Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in Upstream Bio by 95.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company’s stock worth $39,000 after purchasing an additional 1,736 shares during the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.